Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.

ABSTRACT:

Background

Despite improved survival for the patients with diffuse large B-cell lymphoma (DLBCL), the prognosis after relapse is poor. The aim was to identify molecular events that contribute to relapse and treatment resistance in DLBCL.

Methods

We analysed 51 prospectively collected pretreatment tumour samples from clinically high risk patients treated in a Nordic phase II study with dose-dense chemoimmunotherapy and central nervous system prophylaxis with high resolution array comparative genomic hybridization (aCGH) and gene expression microarrays. Major finding was validated at the protein level immunohistochemically in a trial specific tissue microarray series of 70, and in an independent validation series of 146 patients.

Results

We identified 31 genes whose exp

SUBMITTER: Taskinen M 

PROVIDER: S-EPMC3953211 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature